The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial.
Masamichi Mizuma
No relevant relationships to disclose
Fuyuhiko Motoi
No relevant relationships to disclose
Kazuyuki Ishida
No relevant relationships to disclose
Fumiyoshi Fujishima
No relevant relationships to disclose
Shigeru Ottomo
No relevant relationships to disclose
Masaya Oikawa
No relevant relationships to disclose
Takaho Okada
No relevant relationships to disclose
Hiromune Shimamura
No relevant relationships to disclose
Shinichi Takemura
No relevant relationships to disclose
Fuminori Ono
No relevant relationships to disclose
Masanori Akada
No relevant relationships to disclose
Kei Nakagawa
No relevant relationships to disclose
Yu Katayose
No relevant relationships to disclose
Shinichi Egawa
No relevant relationships to disclose
Michiaki Unno
No relevant relationships to disclose